A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers (2014)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1186/1471-2407-14-561
- Subjects: NEOPLASIAS DA TIREOIDE (CLASSIFICAÇÃO); METÁSTASE NEOPLÁSICA; CARCINOMA MEDULAR (QUIMIOTERAPIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: BMC Cancer
- ISSN: 1471-2407
- Volume/Número/Paginação/Ano: v. 14, n. 561, p. (online), 2014
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
HALPERIN, Daniel M. et al. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer, v. 14, n. 561, p. (online), 2014Tradução . . Disponível em: https://doi.org/10.1186/1471-2407-14-561. Acesso em: 04 mar. 2026. -
APA
Halperin, D. M., Phan, A. T., Hoff, A. O., Aaron, M., Yao, J. C., & Hoff, P. M. . (2014). A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer, 14( 561), (online). doi:10.1186/1471-2407-14-561 -
NLM
Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM . A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers [Internet]. BMC Cancer. 2014 ; 14( 561): (online).[citado 2026 mar. 04 ] Available from: https://doi.org/10.1186/1471-2407-14-561 -
Vancouver
Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM . A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers [Internet]. BMC Cancer. 2014 ; 14( 561): (online).[citado 2026 mar. 04 ] Available from: https://doi.org/10.1186/1471-2407-14-561 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre o DOI: 10.1186/1471-2407-14-561 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
